Financial Reports and Presentations

2005

2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
1970
All years

Type of information

Interim reports
Annual reports
Presentations
Other

	Report
September 27, 2005Annual Report 2004 / 2005

Investor contact

[email protected]

+46 18-50 54 40

Subscribe to our news

Investors

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Vivesto is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer.

The company has a portfolio of projects with the potential of offering cancer patients with unmet medical needs new treatment alternatives. Vivesto has a track-record of developing drugs from the preclinical stage, through clinical development to regulatory approval.

Vivesto’s most advanced program Apealea® (paclitaxel micellar) has been granted market approval in the EU as a treatment for adult patients suffering from the first relapse of platinum sensitive epithelial ovarian cancer, or primary peritoneal cancer or fallopian tube cancer. Other clinical development programs include Cantrixil for late-stage ovarian cancer, and Docetaxel micellar, in development for advanced prostate cancer. Moreover, the company is developing Paccal Vet (paclitaxel micellar) for malignant melanoma and hemangiosarcoma in dogs. Vivesto has developed proprietary drug delivery technologies designed to improve solubility of various active pharmaceutical ingredients.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com